Wanneroo herbalist talks up 55 years in business – PerthNow

A MASTER herbalist has built her family business from the ground up, offering alternative medicine for more than 50 years.

Kathleen Dunn, who recently turned 80, has been running Dunns Herbal Clinic in Wanneroo since 1983.

She said it was an accomplishment for her to still be working at the Badgerup Road clinic and farm at her age.

Im still out in the garden, still do all the iridology and reading eyes, the tongue and take the pulses, she said.

From iridology, a detailed analysis of eyes, to selling herbal tonics, Mrs Dunn has been working every day, except Sundays, for 55 years.

Originally from Melbourne, Mrs Dunn said she started learning about herbs from her grandfather and has been operating a herbal clinic since 1965.

In 1975, we came over to Perth and we started a clinic in Scarborough, she said.

We bought this (Wanneroo) property in 1983, and then we moved here.

The property was developed to grow herbs used for formulas but Mrs Dunn said it took some effort for the family to start the business.

This (property) was just horse paddocks, there was nothing here except three trees that were out here, she said.

When we started here, the soil was extremely low, you could pick it up and itll blow away.

Then gradually by using mulch and straw...we built up the soil.

Dunns Herbal clinic sells standard remedies in its shop but Mrs Dunn also conjures up formulas specific to a customer.

We have things where when the person comes for their iridology, its an individual mixture, Mrs Dunn said.

Its a formula only for them and every time they come, the formula changes slightly because of the seasons.

Mrs Dunn said most customers found her through word of mouth and many had stayed for decades.

Mrs Dunn was featured on the front page of sister paper the Joondalup Times in an article about her business in February 1995.

A lot of people have been with me for 20 years, she said.

Ive got one man who, for over 30 years, has been coming to me and hes in his 80s.

Mrs Dunn will hold a 10-week herbal course in September after having to postpone it due to the COVID-19 pandemic.

Read the original:

Wanneroo herbalist talks up 55 years in business - PerthNow

My wife hid her cancer from me and wants me to keep it a secret – The Guardian

The dilemma Last week I discovered that my wife of 40 years has had breast cancer for two years. She claims she kept it a secret from me in order not to upset me or our adult children. A few days later, we discovered the cancer has progressed to her bones.

I have to come to terms with the fact that I will probably soon be a widower, but also with the emotions surrounding my exclusion from the illness. Were it not for the fact that these last two years have probably been our best ever, this would feel like the ultimate betrayal of trust. Im convinced that one of the reasons she hid this from me was because she treated it exclusively with alternative medicine and knew I would oppose this.

Many of my emotions are unacceptable in the context of illness and bereavement. Anger at her lack of trust in me isnt a good companion to sadness. My tears alternate with resentment and the mixture is difficult to reconcile. Whereas she wants to stay positive, I know that the prognosis is quite the opposite. Added to my disarray is the fact that she wants no one else to know about her situation. To avoid lying and faking, I have cut off activities with my closest friends, so I now have to deal with this alone. Any advice will be appreciated.

Mariella replies Im so sorry. This is a sad story for all concerned and particularly, of course, your wife. I totally understand your feelings of betrayal and bewilderment. Were the circumstances different or the prognosis less bleak I would definitely advise that you express your frustration in no uncertain terms. However, based on what youve told me, I dont think there is room for anyone elses feelings but hers at the moment.

Until youve had a brush with your own mortality its impossible to know how you will react. Pledging our troth, promising to care for each other in sickness and in health, are well meant in the moment and indicative of our best intentions. To become a couple is seen as a chance to become one, and described as such in most marriage services, but, as any divorcee will tell you, that state of elevated congress is rarely achieved and nigh on impossible to sustain. For most of us our lives will be lived out in tolerable companionship. Even in the closest seeming couples most of what we think and feel would come as a total surprise, shock or indeed betrayal to our dearly beloveds. I say all this to try to put your wifes behaviour into some context, because I am pretty sure that quite a lot of your time at the moment is spent scrambling around for an explanation.

Her choice to keep her illness from you is puzzling, but there are mitigating factors that we have to try to understand in order to see her side of the picture. While perhaps misplaced, the sheer bravery of enduring these last two years without burdening anyone with her diagnosis is impressive. Its not the right thing to do, but it takes an enormous amount of courage not to seek out the support of those closest to you when the bottom falls out of your world. While I entirely empathise with your feelings, I do have to highlight the price in loneliness and grief your wife must have paid for that decision.

There are no unacceptable emotions in the face of illness and bereavement, neither for you nor for her. I suspect that, despite the courage its taken to conceal what is going on, its fear that prompted her to stay silent. The most agonising part of this is that it really wont help either of you to rake over those resentments. We are all able to play an important role in the lives of those we love but, ultimately, even the most intimately entwined couples make their own choices. Your wife may have cause to regret the course shes embarked on in terms of treatment, but living with our decisions is part of adulthood, and even more so when it comes to life and death.

As youve said, the prognosis doesnt sound good, but shes also right in being allowed to choose her narrative, and her desire to stay positive has much to recommend it. That said, demanding total secrecy borders on the inexcusably selfish. Others need to be allowed to prepare themselves for the brutal battle ahead and the possibility of loss. The first to be considered alongside you, are your children. I lost my father overnight literally at the age of 15. It was world-shattering and Id swap anything for the opportunity to prepare and say goodbye rather than suffer that absolute, unfathomable disappearing act.

Your wife may not want attention and may believe that the best way is her way, but as a parent you cant deny your kids the right to walk with her as far as they can. Id also encourage her to get in touch with an organisation such as Macmillan, who can offer help and advice. What your wife is going through needs to be recognised and reconciled, not only for those who will live on but also for her sake, to take as much weight as you can off her shoulders as she walks a road none of us will escape.

If you have a dilemma, send a brief email to mariella.frostrup@observer.co.uk. Follow her on Twitter @mariellaf1

See the article here:

My wife hid her cancer from me and wants me to keep it a secret - The Guardian

Global Chiropractic Medicine Market to Witness Heightened Growth During the Period 2018 2026 – Research Newspaper

Chiropractic Medicine is an alternate form of medicine used in the diagnosis and treatment of diseases associated with the musculoskeletal system by using hands-on spinal manipulation and other alternative techniques. Chiropractic medicine is primarily used as an alternative to pain relief for muscles, joints, bones, or connective tissue. It can also be used sometimes in combination with the conventional medical treatment. The common and well known therapeutic procedures performed by chiropractic doctors is spinal manipulation. The technique of chiropractic medicine focuses on enabling the body to heal itself without surgery and conventional medication by restoring the mobility of joints which got restricted by tissue injury due to a traumatic event.

The goal of chiropractic medicine is to correct alignment problems, relaxes body and support bodys natural ability to heal itself. Chiropractic doctors evaluate patients through the medical examination, laboratory tests, x-rays, etc. and after taking the complete history and diagnosing a patient, the doctor describes the comprehensive treatment plan and recommend therapeutic exercise along with nutritional, dietary and lifestyle counselling. The chiropractic medicine is used to compliment or support the medical treatment but in many cases, the chiropractic therapy may be the principal method of treatment.

Chiropractic Medicine Market: Drivers & Restraints

The main driving factor for the chiropractic medicine market is the relief from taking medications. Multiple studies also prove the safety of chiropractic treatments than any other commonly used medical treatments; including medications, injections and surgeries for similar conditions. These factors also drive the market for chiropractic medicine market. Along with this, increasing geriatric population, increasing openness to alternative medicines and rise in disposable income also supports the market of chiropractic medicines. However, several side effects associated with the treatment, such as, aching or soreness in the spinal joints or muscles, may restrict the market growth. Unavailability of services in low and middle income countries also restrain the global chiropractic medicine market growth.

To remain ahead of your competitors, request for a sample [emailprotected]

https://www.persistencemarketresearch.com/samples/23116

Chiropractic Medicine market: Segmentation

By Disease Type:

By Age Group:

By End Users

The cost of chiropractic services varies from region to region and form the service type. It is one of the major three healing professions of western world. Chiropractic physicians are trained in providing diagnostic, therapeutic & rehabilitative services along with nutritional, dietary and lifestyle counselling. In context to the rising healthcare costs, the chiropractic medicine can also be seen as an inexpensive and relatively effective treatment method. The market for chiropractic medicines is growing with increasing networking and proven results. The approach followed by one practitioner decides its sales performance and helps in developing customer base.

To receive extensive list of important regions, Request Methodology here @

https://www.persistencemarketresearch.com/methodology/23116

Geographically, the market for chiropractic medicine can be segmented into five regions, North America, Latin America, Europe, Asia Pacific and Middle East & Africa. North America has the highest market share in the global chiropractic medicine owing to the easy access to services and favorable reimbursement scenario. There are over 70,000 licensed chiropractors working in the United States today. This is followed by the European market due to the existence of many healthcare facilities providing chiropractic medicine services. Asia Pacific is expected to represent a stable growth rate during the forecast period supported by the increasing investment in healthcare facilities and rise in the healthcare spending. Latin America followed by MEA represents a slow growth rate in the chiropractic medicines market because of the out of pocket spending and less availability of these services in the region.

Some of the service providers in the chiropractic medicine include Back to Natural Chiropractic, Alberta Blue Cross, Dr. Spine Clinic, Hampstead Chiropractic Clinic, ChiroMatrix, Manors Chiropractic Clinic, Complete Care Chiropractic and Jandakot Chiropractic Clinic etc. There are however not any international service provider in the chiropractic medicine and vary from region to region.

You Can Request for TOC Here @

https://www.persistencemarketresearch.com/toc/23116

Continued here:

Global Chiropractic Medicine Market to Witness Heightened Growth During the Period 2018 2026 - Research Newspaper

Digital Coin Market to Witness Unprecedented Growth in Coming Years 2024 | Bitcoin, Ethereum, Ripple, Litecoin, Dogecoin, Dash – Bulletin Line

TheDigital Coin Marketresearch Report is a valuable supply of perceptive information for business strategists. This Premium Tyres Market study provides comprehensive data which enhances the understanding, scope and application of this report.

The key market segments along with its subtypes are provided in the report. This report especially focuses on the dynamic view of the market, which can help to manage the outline of the industries. Several analysis tools and standard procedures help to demonstrate the role of different domains in market. The study estimates the factors that are boosting the development of Digital Coin companies.

You can get the sample copy of this report now @https://www.reportsintellect.com/sample-request/987228

Key Companies Covered : Bitcoin, Ethereum, Ripple, Litecoin, Dogecoin, Dash

You get the detailed analysis of the current market scenario for Digital Coin and a market forecast till 2024 with this report. The forecast is also supported with the elements affecting the market dynamics for the forecast period. This report also details the information related to geographic trends, competitive scenarios and opportunities in the Digital Coin market. The report is also equipped with SWOT analysis and value chain for the companies which are profiled in this report.

Most Important Types : P2P Coins, Type II

Most Important Application : Online transaction, Application 2

Get Instant discount @https://www.reportsintellect.com/discount-request/987228

Global Digital Coin Market Size, Status and Forecast 2019 2024

1 Market Overview

2 Manufacturers Profiles

3 Global Digital Coin Sales, Revenue, Market Share and Competition by Manufacturer

4 Global Digital Coin Market Analysis by Regions

5 North America Digital Coin by Countries

6 Europe Digital Coin by Countries

7 Asia-Pacific Digital Coin by Countries

8 South America Digital Coin by Countries

9 Middle East and Africa Digital Coin by Countries

10 Global Digital Coin Market Segment by Type

11 Global Digital Coin Market Segment by Application

12 Digital Coin Market Forecast

13 Sales Channel, Distributors, Traders and Dealers

14 Research Findings and Conclusion

15 Appendixes

Reasons for Buying this Report:

About Us:

Reports Intellect is your one-stop solution for everything related to market research and market intelligence. We understand the importance of market intelligence and its need in todays competitive world.

Our professional team works hard to fetch the most authentic research reports backed with impeccable data figures which guarantee outstanding results every time for you.

So whether it is the latest report from the researchers or a custom requirement, our team is here to help you in the best possible way.

Contact Us:

[emailprotected]

PH +1-706-996-2486

US Address:

225 Peachtree Street NE,

Suite 400,

Atlanta, GA 30303

Read this article:

Digital Coin Market to Witness Unprecedented Growth in Coming Years 2024 | Bitcoin, Ethereum, Ripple, Litecoin, Dogecoin, Dash - Bulletin Line

Litecoin (LTC) Down $0.03 in Last 4 Hours, Underperforms All Top Cryptos to Start the Day; Started Today Down 1.13% – CFDTrading

Litecoin 4 Hour Price Update

Updated July 30, 2020 07:20 AM GMT (03:20 AM EST)

Litecoin came into the current 4 hour candle down 0.05% ($0.03) from the open of the previous 4 hours, marking the 3rd candle in a row a decrease has occurred. Relative to other instruments in the Top Cryptos asset class, Litecoin ranked 4th since the previous 4 hours in terms of percentage price change.

The choppiness in the recent daily price action of Litecoin continues; to start today, it came in at a price of 55.22 US dollars, down 1.13% ($0.63) since the previous day. The change in price came along side change in volume that was down 47.12% from previous day, but up 236.77% from the Wednesday of last week. Those trading within the Top Cryptos asset class should know that Litecoin was the worst performer in the class during the previous day. Here is a daily price chart of Litecoin.

The clearest trend exists on the 14 day timeframe, which shows price moving up over that time. Also of note is that on a 90 day basis price appears to be forming a base which could the stage for it being a support/resistance level going forward. For additional context, note that price has gone up 7 out of the past 14 days.

Behold! Here are the top tweets related to Litecoin:

@RichardHeartWin @SatoshiLite Cant imagine where Litecoin would be if @SatoshiLite hadnt dumped ALL his Litecoin at the top. Will it ever recover? We shall see! Thankfully I got into Litecoin early before the pump of 2017 but I flipped all my Litecoin for #Hex and never looked back. Best move I ever made!

@SatoshiLite litecoin is the only coin i will forever hate. Being dumped on the top by the founder and he claims it was a due to a conflict of interest is pure bs. I would of respected more if he had said that he was takin profits.

@Asadharari @Venkate11772346 I believe in a mega bullrun litecoin will outperform bitcoin in % increase. If btc doubles last bullrun price to 40k then litecoin can reach 1k.We just never know how this bull run will play out. Its my belief under the conditions next run will make 2017 look like a warm up

As for a news story related to Litecoin getting some buzz:

Litecoin Foundation Donate crypto at Blockchair Donut

Support the nonprofit leading development and security of the Litecoin global payment network.David provides a monthly progress report which you can read on litecointalk.io In addition, The Litecoin Foundation helps to support adoption and align key partnerships to give Litecoin users financial tools to help with growth of the currency.

Follow this link:

Litecoin (LTC) Down $0.03 in Last 4 Hours, Underperforms All Top Cryptos to Start the Day; Started Today Down 1.13% - CFDTrading

Cryptocurrency Market Analysis By Distribution Channel, Region And Forecast From 2020 To 2025|ZEB IT Service, Coinsecure, Coinbase, Bitstamp,…

Note: Due to the pandemic, we have included a special section on the Impact of COVID 19 on the CryptocurrencyMarket which would mention How the Covid-19 is Affecting the Industry, Market Trends and Potential Opportunities in the COVID-19 Landscape, Key Regions and Proposal for Cryptocurrency Market Players to battle Covid-19 Impact.

The CryptocurrencyMarket report is compilation of intelligent, broad research studies that will help players and stakeholders to make informed business decisions in future. It offers detailed research and analysis of key aspects of the Cryptocurrency market. Readers will be able to gain deeper understanding of the competitive landscape and its future scenarios, crucial dynamics, and leading segments of the global Cryptocurrency market. Buyers of the report will have access to accurate PESTLE, SWOT and other types of analysis on the global Cryptocurrency market. Moreover, it offers highly accurate estimations on the CAGR, market share, and market size of key regions and countries. Players can use this study to explore untapped Cryptocurrency markets to extend their reach and create sales opportunities.

The study encompasses profiles of major Companies/Manufacturers operating in the global Cryptocurrency Market.Key players profiled in the report include:ZEB IT Service, Coinsecure, Coinbase, Bitstamp, Litecoin, Poloniex, BitFury Group, Unocoin Technologies Private, Ripple, OKEX Fintech Company, Bitfinex and More

Get PDF Sample Copy of the Report to understand the structure of the complete report (Including Full TOC, List of Tables & Figures, Chart):https://www.marketinforeports.com/Market-Reports/Request-Sample/129997

Market By Product Types:Bitcoin (BTC)Ether (ETH)Litecoin (LTC)Others

Market By Applications:TransactionInvestmentOthers

To get Incredible Discounts on this Premium Report, Click Here @ https://www.marketinforeports.com/Market-Reports/Request_discount/129997

The authors of the report have analyzed both developing and developed regions considered for the research and analysis of the global Cryptocurrency market. The regional analysis section of the report provides an extensive research study on different regional and country-wise Cryptocurrency industry to help players plan effective expansion strategies.

Regions Covered in the Global Cryptocurrency Market: The Middle East and Africa (GCC Countries and Egypt) North America (the United States, Mexico, and Canada) South America (Brazil etc.) Europe (Turkey, Germany, Russia UK, Italy, France, etc.) Asia-Pacific (Vietnam, China, Malaysia, Japan, Philippines, Korea, Thailand, India, Indonesia, and Australia)

Years Considered to Estimate the Market Size:History Year: 2015-2019Base Year: 2019Estimated Year: 2020Forecast Year: 2020-2025

For More Information:https://www.marketinforeports.com/Market-Reports/129997/Cryptocurrency-market

Customization of the Report:Market Info Reports provides customization of reports as per your need. This report can be personalized to meet your requirements. Get in touch with our sales team, who will guarantee you to get a report that suits your necessities.

Get Customization of the [emailprotected]:https://www.marketinforeports.com/Market-Reports/Request-Customization/129997/Cryptocurrency-market

Get in Touch with Us :Mr. Marcus KelCall: +1 915 229 3004 (U.S)+44 7452 242832 (U.K)Email: [emailprotected]Website: http://www.marketinforeports.com

Excerpt from:

Cryptocurrency Market Analysis By Distribution Channel, Region And Forecast From 2020 To 2025|ZEB IT Service, Coinsecure, Coinbase, Bitstamp,...

Cryptocurrency Market Current Trends and Future Aspect Analysis 2020 2025 – Owned

This research report on the Global Cryptocurrency Market offers in-depth research about market conditions, market share, and market segmentation. This research report covers the complete landscape of this market with its growth prospects during the forecast period. In addition, the report also comprises a discussion of the major players operating in this Global Cryptocurrency Market. It also offers granular analysis of market segmentation, share, regional analysis, as well as revenue forecasts. Moreover, the Global Cryptocurrency Market report offers a basic overview of the market such as applications, definitions, classifications, as well as industry chain structure. This study is specially offered for the global markets including key region development status, development trends, and competitive landscape analysis. The report also focuses on the major regions such as North America, Europe, Asia Pacific, and MEA. Likewise, this report contains major drivers, opportunities, restraints, and threats for major vendors.

Request a sample of this report @ https://www.orbisresearch.com/contacts/request-sample/4919454?utm_source=Manjiri

This report also caters several development plans and policies with cost manufacturing processes & cost structures. The study also provides data about importation and exportation consumption, revenue, cost, supply & demand figures, and gross margins. The Global Cryptocurrency Market report offers key statistics on the market status. Likewise, the report comprises drivers and restraints of the Global Cryptocurrency Market along with the impact on the demand during the prediction period.

Key vendors/manufacturers in the market:

ZEB IT ServiceCoinsecureCoinbaseBitstampLitecoinPoloniexBitFury GroupUnocoin Technologies PrivateRippleOKEX Fintech CompanyBitfinex

Browse the complete report @ https://www.orbisresearch.com/reports/index/2015-2025-global-cryptocurrency-market-research-by-type-end-use-and-region-covid-19-version?utm_source=Manjiri

Moreover, the report comprises the analysis of opportunities available in the Global Cryptocurrency Market on the global level. Furthermore, this research report provides an extensive investigation of the Global Cryptocurrency Market along with the future projections to estimate the venture feasibility. In addition, the study comprises both qualitative and quantitative study of the Global Cryptocurrency Market during the prediction period.

Global Market By Type:

Bitcoin (BTC)Ether (ETH)Litecoin (LTC)Others

Global Market By Application:

TransactionInvestmentOthers

This study also offers significant information about market scope and opportunities for growth of the Global Cryptocurrency Market. Likewise, it offers complete insights into market barriers as well as the impact of regulatory framework to provide the broad market landscape. In addition, the Global Cryptocurrency Market report provides a detailed information about market players along with the strategies they implemented to gain market existence. The report includes precise market estimations depending on current market status and future market forecasts. Moreover, the Global Cryptocurrency Market report gives inclusive details about the industry with competitive landscape and an in-depth analysis of SWOT and Porters Five Forces model for the Global Cryptocurrency Market. Additionally, this report includes brief market segmentation study and all the segments are specified on the basis of market size, growth rate, as well as general attractiveness.

Make an enquiry of this report @ https://www.orbisresearch.com/contacts/enquiry-before-buying/4919454?utm_source=Manjiri

About Us :

Orbis Research (orbisresearch.com) is a single point aid for all your market research requirements. We have vast database of reports from the leading publishers and authors across the globe. We specialize in delivering customized reports as per the requirements of our clients. We have complete information about our publishers and hence are sure about the accuracy of the industries and verticals of their specialization. This helps our clients to map their needs and we produce the perfect required market research study for our clients.

Contact Us :

Hector CostelloSenior Manager Client Engagements4144N Central Expressway,Suite 600, Dallas,Texas 75204, U.S.A.Phone No.: USA: +1 (972)-362-8199 | IND: +91 895 659 5155

Go here to see the original:

Cryptocurrency Market Current Trends and Future Aspect Analysis 2020 2025 - Owned

Scipher Medicine Announces Publication of Clinical Study Validating PrismRA, a Blood Test Predicting Non-Response to TNF Inhibitor Therapies in…

PrismRA identifies patients 6.6 times less likely to respond to TNFi therapy

Scipher Medicine, a precision immunology company that helps match patients with their most effective therapy, today announced successful results from the PrismRA clinical validation study. The publication titled "Clinical validation of a blood-based predictive test for stratification of response to tumor necrosis factor inhibitor therapies in rheumatoid arthritis patients" was published in Network and Systems Medicine.

The study, co-authored by scientists from Scipher Medicine and experts in the field of clinical rheumatology, met the endpoint of determining a molecular signature that accurately predicts rheumatoid arthritis (RA) patients who will fail to respond adequately to tumor necrosis factor inhibitor (TNFi) therapies. Empowered with this information, healthcare providers can prescribe alternative therapy from day one without first having to cycle through and fail multiple TNFi drugs.

PrismRA uses whole blood gene expression data to identify if a patients molecular disease biology is suited to TNFi therapy. PrismRA is expected to be introduced to rheumatology practices later this summer and has the potential to improve treatment decisions and reduce trial-and-error attempts with treatments that are unlikely to be effective based on a patients unique biology.

"About 90% of patients with rheumatoid arthritis are prescribed TNFi therapy after failing disease-modifying anti-rheumatic drugs (DMARDs), such as methotrexate. However, a majority of patients fail to achieve a clinically meaningful change," said Dr. Slava Akmaev, Chief Technology Officer of Scipher Medicine. "The need for precision medicine in RA and other complex diseases has never been more obvious, particularly now with provider access being severely limited due to heightened COVID-19 pandemic concerns. PrismRA has the ability to limit TNFi drug cycling and help patients manage their disease more effectively."

"In this study, TNFi therapies failed to help nearly 70% of the unstratified patient population reach an adequate response. The PrismRA disease signature test could have prevented many of these individuals from taking a drug that did not adequately ameliorate the signs and symptoms of their disease," said Jeffrey Curtis, M.D., M.S., MPH, Professor of Medicine in the Division of Clinical Immunology and Rheumatology at the University of Alabama at Birmingham. "RA is a complex disease with multiple biological factors implicated in disease progression and severity. A test such as PrismRA has the potential to be a powerful tool for treating patients with the right treatment at the right time."

PrismRA was validated using the Comparative Effectiveness Registry to Study Therapies for Arthritis and Inflammatory Conditions (CERTAIN) data set of 175 biologic-nave RA patients from the Consortium of Rheumatology Researchers of North America (CORRONA). PrismRA identified patients who were unlikely to have an adequate response to TNFi therapies with a positive predictive value (PPV) of 89.7% and specificity of 86.8%. Overall, a patient identified by PrismRA to be a non-responder is 6.6 times more likely to inadequately respond to a TNFi therapy compared to someone lacking that molecular signature.

About PrismRA

PrismRA, a molecular signature test, is a revolutionary advancement bringing precision medicine to the treatment of rheumatoid arthritis, which affects 1.3 million patients in the United States alone. From a routine blood draw, PrismRA analyzes an individual's molecular signature, helping identify who is unlikely to adequately respond to TNFi therapy, the worlds largest selling drug class. Providers now have objective data to guide therapeutic decision-making and give patients the best chance of achieving treatment targets and improving clinical outcomes. For more information, please visit http://www.PrismRA.com.

About Scipher Medicine

Scipher Medicine, a precision immunology company, holds the fundamental belief that patients deserve simple answers to treatment options based on scientifically backed data. Leveraging our proprietary Network Medicine platform and artificial intelligence, we commercialize blood tests revealing a patients unique molecular disease signature and match such signature to most effective therapy, ensuring optimal treatment from day one. The unprecedented amount of patient molecular data generated from our tests further drives development of novel and more effective therapeutics. We partner with payers, providers and pharma along the health care value chain to bring precision medicine to autoimmune diseases.

Scipher Medicine is backed by Khosla Ventures, Northpond Ventures and UnitedHealth Group. Visit http://www.sciphermedicine.com and follow Scipher on Twitter, Facebook and LinkedIn.

View source version on businesswire.com: https://www.businesswire.com/news/home/20200728005364/en/

Contacts

Media Contact: Cassidy McClainCassidy@canalecomm.com 619.849.6009

Company contact:Andrea Mooreandrea.moore@sciphermedicine.com 801-209-1175

Here is the original post:

Scipher Medicine Announces Publication of Clinical Study Validating PrismRA, a Blood Test Predicting Non-Response to TNF Inhibitor Therapies in...

Biomedical journal edited at School of Medicine and Perinatology Research Branch receives top ranking – The South End

The American Journal of Obstetrics & Gynecology, edited at the Wayne State University School of Medicine and the Perinatology Research Branch, has received the highest Impact Factor of all journals within the discipline reporting original research.

Last month, Journal Citation Reports announced that the Impact Factor of AJOG is now 6.502, placing it first among journals publishing original research in obstetrics and gynecology.

The Impact Factor, the yearly average number of citations that articles published in the last two years in a given journal received, is provided annually by Journal Citation Reports. The measure is considered an index of prestige of a journal.

AJOG ranked top in Eigenfactor score, a sophisticated measure of journal impact, calculated by taking into account the impact factor of the citing journal and adjusting for self-citations. AJOG also had the highest number of citations among all journals in the discipline for 2019, with a total of 41,245.

AJOGs editor-in-chief for Obstetrics is Roberto Romero, M.D., D.Med.Sci., chief of the Perinatology Research Branch of the National Institute of Child Health and Human Development/National Institutes of Health, and professor of Molecular Obstetrics and Genetics at the Wayne State University School of Medicine. The editor-in-chief for Gynecology is Catherine Bradley, M.D., MSCE, professor of Obstetrics and Gynecology, Epidemiology, and Urology at the University of Iowa.

"With a distinguished past, AJOG is deeply committed to innovation and publishing the best groundbreaking research that improves the health care of women, Dr. Romero said.

Known as the Gray Journal, the American Journal of Obstetrics & Gynecology has been the premier academic journal in the discipline for more than 150 years. More than 41,000 obstetricians and gynecologists worldwide receive the print version.

Among the groundbreaking discoveries that have changed the practice of medicine and the lives of women and their families that have been published on its pages include:

The Pap smear for the detection of cervical cancer; The assay for the detection of early pregnancy (pregnancy test), used worldwide; Polycystic ovarian disease, which affects 5% to 10% percent of women of reproductive age; The first graphic display of the labor curve, which has led to partograms in every labor and delivery unit; and The importance of progesterone in pregnancy maintenance.

This year, AJOG has published:

A randomized clinical trial of cervical cerclage in twin gestations with a dilated cervix; Vaginal progesterone for the prevention of preterm birth in twin gestations; The use of a rapid point-of-care test to assess intra-amniotic inflammation in patients with ruptured membranes; and The outcome of COVID-19 in pregnant women.

The PRB of NICHD/NIH is housed at Wayne State University and the Detroit Medical Center, strategically located to serve a high-risk pregnant population. The Perinatology Research Branch has produced groundbreaking clinical and translational research, and cared for more than 25,000 mothers in Detroit.

Original post:

Biomedical journal edited at School of Medicine and Perinatology Research Branch receives top ranking - The South End

Myriad Launches Proprietary AMPLIFY Technology, Further Increasing the Performance of its Prequel NIPS Test – GlobeNewswire

SALT LAKE CITY, July 29, 2020 (GLOBE NEWSWIRE) -- Myriad Genetics, Inc. (NASDAQ: MYGN), a leader in molecular diagnostics and precision medicine, announced today that the company has launched its proprietary AMPLIFY technology, which further increases the performance of its Prequelnoninvasive prenatal screening (NIPS) test. The proprietary AMPLIFY process increases the fetal fraction of a NIPS sample by preferentially sequencing the fetal cell-free DNA fragments that circulate in a mothers blood. AMPLIFY technology enables more accurate detection of fetal chromosome abnormalities. In the analytical validation involving samples from more than 1,000 pregnant women, fetal fraction is 2.3 times greater on average with AMPLIFY than with standard NIPS. This improvement reduces false positive and false negative resultsincluding for common aneuploidies, expanded aneuploidies, microdeletions and a babys sex. For instance, false negative performance in common aneuploidies improves 45x with AMPLIFY technology. Additionally, no samples powered by AMPLIFY technology had a fetal fraction below four percent. Other laboratories may fail samples with less than four percent fetal fraction.

Prequel already provided highly accurate results and this proprietary technology further increases the sensitivity of our test, said Nicole Lambert, president of Myriad International, Oncology and Womens Health. With AMPLIFY, Prequel maintains an industry-leading low rate of failed samplesdelivering results to 99.9 percent of patients. The important clinical benefits are that each woman who receives the test can expect highly accurate NIPS results, regardless of body mass index (BMI), race, or ethnicity.

Up to 50 percent of pregnant women present with high BMI to their healthcare provider. Studies have demonstrated that BMI is not evenly distributed across ethnicities, and up to 24 percent of women with high BMI will not receive a result on standard NIPS platforms due to low fetal fraction. Women who dont receive a result may do no further prenatal screening at all; they may go through subsequent rounds of NIPS, or they may undergo invasive procedures such as an amniocentesis or chorionic villus sampling, which can increase the risk of miscarriage and add unnecessary expense to the US healthcare system. Prequel with AMPLIFY technology overcomes the limitations of standard NIPS in order to provide equity of care to pregnant women.

About Prequel Prenatal ScreenThe Myriad Prequel Prenatal Screen is a non-invasive prenatal screen (NIPS) that uses cell-free DNA (cfDNA) to determine if a pregnancy is at an increased risk for chromosome abnormalities, such as Down syndrome. Compared to screening methods which use maternal age, ultrasound and serum screening, Prequel has been shown to be superior than by achieving a lower false-positive rate and false-negative rate than these other methods. Among other NIPS, Prequel has an industry leading test failure rate of 0.1 percent. The Prequel Prenatal Screen can be ordered with the Foresight Carrier Screen and offered to all women, including those with high body mass index, and ovum donor or a twin pregnancy.

About Myriad GeneticsMyriad Genetics Inc., is a leading personalized medicine company dedicated to being a trusted advisor transforming patient lives worldwide with pioneering molecular diagnostics. Myriad discovers and commercializes molecular diagnostic tests that: determine the risk of developing disease, accurately diagnose disease, assess the risk of disease progression, and guide treatment decisions across six major medical specialties where molecular diagnostics can significantly improve patient care and lower healthcare costs. Myriad is focused on three strategic imperatives: transitioning and expanding its hereditary cancer testing markets, diversifying its product portfolio through the introduction of new products and increasing the revenue contribution from international markets. For more information on how Myriad is making a difference, please visit the Company's website: http://www.myriad.com.

Myriad, the Myriad logo, BART, BRACAnalysis, Colaris, Colaris AP, myPath, myRisk, Myriad myRisk, myRisk Hereditary Cancer, myChoice, myPlan, BRACAnalysis CDx, Tumor BRACAnalysis CDx, myChoice CDx, Vectra, Prequel, Foresight, GeneSight, riskScore and Prolaris are trademarks or registered trademarks of Myriad Genetics, Inc. or its wholly owned subsidiaries in the United States and foreign countries. MYGN-F, MYGN-G.

Safe Harbor StatementThis press release contains "forward-looking statements" within the meaning of the Private Securities Litigation Reform Act of 1995, including statements related to launch of the Companys proprietary AMPLIFY technology; and the Companys strategic directives under the caption "About Myriad Genetics." These "forward-looking statements" are based on management's current expectations of future events and are subject to a number of risks and uncertainties that could cause actual results to differ materially and adversely from those set forth in or implied by forward-looking statements. These risks and uncertainties include, but are not limited to: uncertainties associated with COVID-19, including its possible effects on our operations and the demand for our products and services; our ability to efficiently and flexibly manage our business amid uncertainties related to COVID-19; the risk that sales and profit margins of our molecular diagnostic tests and pharmaceutical and clinical services may decline; risks related to our ability to transition from our existing product portfolio to our new tests, including unexpected costs and delays; risks related to decisions or changes in governmental or private insurers reimbursement levels for our tests or our ability to obtain reimbursement for our new tests at comparable levels to our existing tests; risks related to increased competition and the development of new competing tests and services; the risk that we may be unable to develop or achieve commercial success for additional molecular diagnostic tests and pharmaceutical and clinical services in a timely manner, or at all; the risk that we may not successfully develop new markets for our molecular diagnostic tests and pharmaceutical and clinical services, including our ability to successfully generate revenue outside the United States; the risk that licenses to the technology underlying our molecular diagnostic tests and pharmaceutical and clinical services and any future tests and services are terminated or cannot be maintained on satisfactory terms; risks related to delays or other problems with operating our laboratory testing facilities and our healthcare clinic; risks related to public concern over genetic testing in general or our tests in particular; risks related to regulatory requirements or enforcement in the United States and foreign countries and changes in the structure of the healthcare system or healthcare payment systems; risks related to our ability to obtain new corporate collaborations or licenses and acquire new technologies or businesses on satisfactory terms, if at all; risks related to our ability to successfully integrate and derive benefits from any technologies or businesses that we license or acquire; risks related to our projections about our business, results of operations and financial condition; risks related to the potential market opportunity for our products and services; the risk that we or our licensors may be unable to protect or that third parties will infringe the proprietary technologies underlying our tests; the risk of patent-infringement claims or challenges to the validity of our patents or other intellectual property; risks related to changes in intellectual property laws covering our molecular diagnostic tests and pharmaceutical and clinical services and patents or enforcement in the United States and foreign countries, such as the Supreme Court decisions in Mayo Collab. Servs. v. Prometheus Labs., Inc., 566 U.S. 66 (2012), Assn for Molecular Pathology v. Myriad Genetics, Inc., 569 U.S. 576 (2013), and Alice Corp. v. CLS Bank Intl, 573 U.S. 208 (2014); risks of new, changing and competitive technologies and regulations in the United States and internationally; the risk that we may be unable to comply with financial operating covenants under our credit or lending agreements; the risk that we will be unable to pay, when due, amounts due under our credit or lending agreements; and other factors discussed under the heading "Risk Factors" contained in Item 1A of our most recent Annual Report on Form 10-K for the fiscal year ended June 30, 2019, which has been filed with the Securities and Exchange Commission, as well as any updates to those risk factors filed from time to time in our Quarterly Reports on Form 10-Q or Current Reports on Form 8-K. All information in this press release is as of the date of the release, and Myriad undertakes no duty to update this information unless required by law.

Visit link:

Myriad Launches Proprietary AMPLIFY Technology, Further Increasing the Performance of its Prequel NIPS Test - GlobeNewswire

Myriad Announces the Launch of a New Radiographic Progression Prognostic Tool, Adding to Clinical Value of Vectra – BioSpace

SALT LAKE CITY, July 28, 2020 (GLOBE NEWSWIRE) -- Myriad Genetics, Inc. (NASDAQ: MYGN), a leader in molecular diagnostics and precision medicine, announced today that the company has launched a new enhancement that is now available on its Vectra test report. The new test report provides an individualized estimate of a patients one-year risk of rapid radiographic progression (RP). The RP result in every report is personalized based on the patients age, gender and adiposity.

We previously presented data demonstrating that Vectra is the best single predictor of joint damage. Inclusion of information on RP risk in the Vectra test report now gives clear insight into both the patients current rheumatoid arthritis (RA) inflammation and the future risk of joint damage, said Mark S. Verratti, president of Myriad Neuroscience and Myriad Autoimmune. With this new product enhancement, Vectra as a prognostic tool can help further guide medical management decisions for patients with RA.In a combined analysis of patients from three studies, 42 percent of patients thought to be in low or moderate disease activity assessed by a traditional disease activity measure were in high disease activity as measured by Vectra, and thus were at risk of irreversible joint damage within one year. Each patient will receive an individualized percentage risk prediction for radiographic progression within one year (see Example 1 below), helping physicians and patients make treatment decisions.

To view Example 1: The Vectra Score correlates to the risk of radiographic progression, please visit the following link: https://www.globenewswire.com/NewsRoom/AttachmentNg/1ed33a2f-4c29-4cbb-8b86-c12f819b9910

RA is an inflammatory autoimmune disease that attacks a patients joints and often affects other organ systems. RA is a contributing condition that leads to increased disability, significant morbidity, increased mortality and financial burden. Lost productivity associated with RA is substantial, with approximately 20-70 percent of individuals working at the time of their RA diagnosis were disabled after seven to 10 years. RA affects roughly more than one million people in the United States. The Vectra Score measures the concentrations of 12 serum biomarkers and an algorithm is applied to these biomarker concentrations to calculate a disease activity score on a scale of 1 to 100. Vectra Disease Activity Levels are as follows: Green = Low: 1 to 29, Orange = Moderate: 30 to 44, Red = High: 45 to 100. The risk of RP is shown as a function of Vectra Score. The definition of RP is a 1-year total Sharp score change of >5 units. Increased risk of RP means a greater chance of irreversible joint damage.

Three out of four rheumatologists have used Vectra and have ordered more than one million tests for their RA patients. The American College of Rheumatology (ACR) includes Multi-Biomarker Disease Activity Score (Vectra) as a disease activity measure that meets minimum standards for regular use for patients with rheumatoid arthritis. Those recommendations were published in the journal Arthritis Care & Research.

About VectraVectra is a multi-biomarker molecular blood test that provides an objective and personalized measure of inflammatory disease activity in patients with rheumatoid arthritis. Vectra demonstrates unsurpassed ability to predict radiographic progression and can help guide medical management decisions to improve patient outcomes. Vectra testing is performed at a state-of-the-art CLIA (Clinical Laboratory Improvement Amendments) facility. Test results are reported to the physician five to seven days from shipping of the specimen. Physicians can receive test results by fax or the private provider web portal, VectraView. For more information on Vectra, please visit: http://www.VectraScore.com.

About Myriad GeneticsMyriad Genetics Inc., is a leading personalized medicine company dedicated to being a trusted advisor transforming patient lives worldwide with pioneering molecular diagnostics. Myriad discovers and commercializes molecular diagnostic tests that: determine the risk of developing disease, accurately diagnose disease, assess the risk of disease progression, and guide treatment decisions across six major medical specialties where molecular diagnostics can significantly improve patient care and lower healthcare costs. Myriad is focused on three strategic imperatives: transitioning and expanding its hereditary cancer testing markets, diversifying its product portfolio through the introduction of new products and increasing the revenue contribution from international markets. For more information on how Myriad is making a difference, please visit the Company's website: http://www.myriad.com.

Myriad, the Myriad logo, BART, BRACAnalysis, Colaris, Colaris AP, myPath, myRisk, Myriad myRisk, myRisk Hereditary Cancer, myChoice, myPlan, BRACAnalysis CDx, Tumor BRACAnalysis CDx, myChoice CDx, Vectra, Prequel, Foresight, GeneSight, riskScore and Prolaris are trademarks or registered trademarks of Myriad Genetics, Inc. or its wholly owned subsidiaries in the United States and foreign countries. MYGN-F, MYGN-G.

Safe Harbor StatementThis press release contains "forward-looking statements" within the meaning of the Private Securities Litigation Reform Act of 1995, including statements related to launch of Radiographic Progression estimates on Vectra test reports; and the Companys strategic directives under the caption "About Myriad Genetics." These "forward-looking statements" are based on management's current expectations of future events and are subject to a number of risks and uncertainties that could cause actual results to differ materially and adversely from those set forth in or implied by forward-looking statements. These risks and uncertainties include, but are not limited to: uncertainties associated with COVID-19, including its possible effects on our operations and the demand for our products and services; our ability to efficiently and flexibly manage our business amid uncertainties related to COVID-19; the risk that sales and profit margins of our molecular diagnostic tests and pharmaceutical and clinical services may decline; risks related to our ability to transition from our existing product portfolio to our new tests, including unexpected costs and delays; risks related to decisions or changes in governmental or private insurers reimbursement levels for our tests or our ability to obtain reimbursement for our new tests at comparable levels to our existing tests; risks related to increased competition and the development of new competing tests and services; the risk that we may be unable to develop or achieve commercial success for additional molecular diagnostic tests and pharmaceutical and clinical services in a timely manner, or at all; the risk that we may not successfully develop new markets for our molecular diagnostic tests and pharmaceutical and clinical services, including our ability to successfully generate revenue outside the United States; the risk that licenses to the technology underlying our molecular diagnostic tests and pharmaceutical and clinical services and any future tests and services are terminated or cannot be maintained on satisfactory terms; risks related to delays or other problems with operating our laboratory testing facilities and our healthcare clinic; risks related to public concern over genetic testing in general or our tests in particular; risks related to regulatory requirements or enforcement in the United States and foreign countries and changes in the structure of the healthcare system or healthcare payment systems; risks related to our ability to obtain new corporate collaborations or licenses and acquire new technologies or businesses on satisfactory terms, if at all; risks related to our ability to successfully integrate and derive benefits from any technologies or businesses that we license or acquire; risks related to our projections about our business, results of operations and financial condition; risks related to the potential market opportunity for our products and services; the risk that we or our licensors may be unable to protect or that third parties will infringe the proprietary technologies underlying our tests; the risk of patent-infringement claims or challenges to the validity of our patents or other intellectual property; risks related to changes in intellectual property laws covering our molecular diagnostic tests and pharmaceutical and clinical services and patents or enforcement in the United States and foreign countries, such as the Supreme Court decisions in Mayo Collab. Servs. v. Prometheus Labs., Inc., 566 U.S. 66 (2012), Assn for Molecular Pathology v. Myriad Genetics, Inc., 569 U.S. 576 (2013), and Alice Corp. v. CLS Bank Intl, 573 U.S. 208 (2014); risks of new, changing and competitive technologies and regulations in the United States and internationally; the risk that we may be unable to comply with financial operating covenants under our credit or lending agreements; the risk that we will be unable to pay, when due, amounts due under our credit or lending agreements; and other factors discussed under the heading "Risk Factors" contained in Item 1A of our most recent Annual Report on Form 10-K for the fiscal year ended June 30, 2019, which has been filed with the Securities and Exchange Commission, as well as any updates to those risk factors filed from time to time in our Quarterly Reports on Form 10-Q or Current Reports on Form 8-K. All information in this press release is as of the date of the release, and Myriad undertakes no duty to update this information unless required by law.

Example 1: The Vectra Score correlates to the risk of radiographic progression

Example 1: The Vectra Score correlates to the risk of radiographic progression

See original here:

Myriad Announces the Launch of a New Radiographic Progression Prognostic Tool, Adding to Clinical Value of Vectra - BioSpace

Dr. Victor J. Thannickal named to lead Deming Department of Medicine – News from Tulane

Victor J. Thannickal, MD, will join School of Medicines John W. Deming Department of Medicine in January 2021.

Victor J. Thannickal, MD, has been named The Harry B. Greenberg Chair in Tulane University School of Medicines John W. Deming Department of Medicine. He joins the university in January 2021.

Thannickal is a professor of medicine and pathology at the University of Alabama at Birmingham (UAB); the Ben Vaughan Branscomb Chair of Medicine in Respiratory Disease; director of the Division of Pulmonary, Allergy, and Critical Care; and vice chair for research, Department of Medicine.

The Department of Medicine is one of the largest clinical departments within the Tulane School of Medicine, with an expansive research program that extends from the basic sciences of physiology and disease to the application of knowledge in clinical and community settings.

Thannickals research focuses on cellular and molecular mechanisms of lung repair and regeneration. Discoveries from this work have led to the identification of a number of drug targets for the treatment of fibrotic lung disease. He has multiple active grants from the National Institutes of Health, including a translational Program Project grant from the National Heart, Lung and Blood Institute.

I am pleased to join an outstanding group of clinicians, educators and scientists within the Deming Department of Medicine at Tulane University, Thannickal said. Tulane has a legendary history of major contributions to science and medicine. I look forward to building on this legacy by establishing leading research and training programs at both the graduate and post-graduate levels. We aspire to make scientific discoveries that address global pandemics and health inequalities, while contributing to the creation of healthier populations worldwide.

A graduate of Oral Roberts University School of Medicine in Tulsa, Oklahoma, Thannickal served a fellowship at Tufts University School of Medicine. Later, he held faculty positions at Tufts, University of Michigan and UAB, where he currently directs the Division of Pulmonary, Allergy, and Critical Care Medicine. Under his leadership, the division has grown to over 75 faculty members and expanded its research and educational programs, including the institution of a highly successful NIH T32 Training Program in Lung Biology and Translational Medicine. Research funding for the division has grown to over $25 million per year under his tenure, making it one of the top-funded divisions in the country. Thannickal has a passion for mentoring and team-building; trainees from his laboratory have moved on to independent careers at multiple academic medical centers across the United States.

We are fortunate to have attracted a leader and innovator of Dr. Thannickals caliber to head the Deming Department of Medicine, said Lee Hamm, MD, senior vice president and dean of the School of Medicine. His collaborative and forward-thinking vision will have an impact not only on our largest department, but across the entirety of Tulane University and the global community we serve.

Thannickal is an elected member of the Association of American Physicians and the American Clinical and Climatological Association. He is the recipient of the American Thoracic Society Recognition Award for Scientific Accomplishments. He currently serves on the editorial boards of the Journal of Clinical Investigation (Consulting Editor), as well those of the American Journal of Respiratory and Critical Care Medicine and the American Journal of Pathology; and is an associate editor of the American Journal of Respiratory Cell and Molecular Biology.

Link:

Dr. Victor J. Thannickal named to lead Deming Department of Medicine - News from Tulane

Inhibiting Key Molecular Chaperone Sensitives Tumors to Radiation Therapy in Animal Models – University of Michigan Health System News

The molecular chaperone protein known as heat shock protein 90 (Hsp90) helps stabilize a number of proteins that are involved in tumor growth. This is why inhibitors that act on the protein have been investigated as potential anti-cancer drugs.

So far, however, the inhibitors developed by various academic groups and pharmaceutical companies have met with limited success due to their high toxicity to normal cells.

Now, a new animal model study from the University of Michigan Rogel Cancer Center suggests Hsp90 inhibitors could help treat cancer in an indirect way. A low dose of a Hsp90 inhibitor known as AT13387 (onalespib) was able to sensitize tumors to radiation therapy, according to findings published in Clinical Cancer Research.

To the best of our knowledge, our study is the first to demonstrate that a sub-cytotoxic concentration of an Hsp90 inhibitor can inhibit the DNA repair process and thus selectively sensitize tumors to radiotherapy, says study senior author Mukesh Nyati, Ph.D., an associate professor of radiation oncology at Michigan Medicine.

The approach led to significant reduction in tumor growth in mouse xenograft models of head and neck squamous cell carcinoma and pancreatic cancer.

The Hsp90 inhibitor compound used in the study was provided by the Cancer Therapy Evaluation Program at the National Institutes of Health.

Paper cited: Low dose Hsp90 inhibitor selectively radiosensitizes HNSCC and Pancreatic xenografts, Clinical Cancer Research. DOI: 10.1158/1078-0432.CCR-19-3102

Read more:

Inhibiting Key Molecular Chaperone Sensitives Tumors to Radiation Therapy in Animal Models - University of Michigan Health System News

Bill Kemp: Forget Whos on first, whos gonna catch it? – The Ledger

Some teams have resorted to utilizing cardboard cutouts of fans. Expect an army of Teddy bears, mannequins and mask-clad puppets marching up the outfield ramp soon.

The stands look like those of a last-place team in September.

With no fans in the seats at major league baseball games, home run balls just clang around in the empty seats before disappearing underneath one. Actually, it looks like giant a pinball machine out there with no one commanding the flippers.

"Tommy can you hear me?"

What a lonely baseball.

The late Detroit Tigers Hall of Fame play-by-play radio announcer Ernie Harwell used to proclaim, "A man from Kalamazoo caught that one," after a foul ball lofted into the jam-packed stands. And it sounded believable to young listeners, whom scratched their heads and wondered, "How did he know that?"

Some teams have resorted to utilizing cardboard cutouts of fans in a stark attempt to create ballpark spirit while missing the aroma of hot dogs, peanuts and liquid libations aiding their cause. Expect an army of Teddy bears, mannequins and mask-clad puppets marching up the outfield ramp real soon.

Maybe franchises could glue gloves onto those cutouts. If the ball bounces or pops in, it belongs to the lucky fan who bank-rolled the knock-off.

Companies might consider purchasing corporate sponsorship boxes and send 20 fortunate employee cutouts clad with its company logo to the game.

How about some famous fans cutouts like Bill Murray, Drew Carey, Tom Selleck and Jerry Seinfeld? Or Eminen and some rock groups to liven up luxury boxes? An Erin Andrews cutout with piped in audio could ask them some baseball trivia during a pitching change.

We need something, because when a historic blast happens, someone or something needs to field it. The fans snag and story is just as intrinsic to the event as well.

Los Angeles Angels first baseman Albert Pujols is just four home runs shy of catching Willie Mays with 660 and moving into fifth place on the all-time home run list. Barring injury or some COVID-crud, this is going down real soon.

So whos gonna catch it unless it leaves the park?

When Babe Ruth entered immortality with his 700th career blast at Navin Field in Detroit, at least 17-year-old Lenny Bielski ran it down and dove underneath a parked car to claim it. According to a 1973 Detroit Free Press interview, Bielski reminisced about the mob which immediately pursued.

"Then a lot of policemen and ushers all grabbed me. They put me on their shoulders and stopped the game and took me into the ballpark and put me in the dugout with Babe Ruth, Joe McCarthy the manager and Lou Gehrig. After the game Babe said, Im gonna give him $120. He didnt have his wallet, though, so he told Gehrig, Ill give that boy a $20 bill,'" said Bielski in the interview.

Did that moment and not-so-lonely ball mean something to him and Ruth? Well, he never spent the $20 even though it was during hub of the Great Depression.

Tigers first baseman Miguel Cabrera just passed Adrian Beltre with a home run Saturday and is 22 round-trippers shy of the exclusive 500 club. He may not have a legitimate shot at 22 on a 60-game schedule, but he needs just 15 more to catch Gehrig and Fred McGriff -- tied for 28th place on the all-time list with 493. Historically, Cabrera bashes one every 18.76 at-bats.

If Miggy hits it, someone has to fetch it, and Bielski doesnt live in the neighborhood anymore.

Maybe they could put a corporate-sponsored cardboard cutout of the Beatles out there dressed in Dr. Peppers Lonely Balls Club fans attire to get a glove on it.

Bill Kemp can be reached at Bill.Kemp@theledger.com; follow him on Twitter @BillKempSports

Read the rest here:

Bill Kemp: Forget Whos on first, whos gonna catch it? - The Ledger

Haggerty: Rask’s legacy will very much be impacted by this playoff run – NBC Sports Boston

Its no stretch to say that a great deal of Tuukka Rasks ultimate legacy with the Bruins is tied up in the unprecedented 2020 Stanley Cup playoffs inside the bubble.

Sure, the 33-year-old is a Vezina Trophy finalist this season for the second time in his NHL career and is essentially in a two-man race with Winnipegs Connor Hellebuyck for the ultimate piece of goaltending hardware this season. The .929 save percentage and NHL-leading 2.25 goals against average speak for themselves about his dominance this year while largely splitting time with backup goalie Jaroslav Halak in a nearly equal split of playing time.

Truthfully, the regular season accolades go on and on for Rask as he continues to prove hes the best regular season goaltender in Bruins franchise history. Hes the all-time winningest goalie in Bruins history with 291 wins, and has the most games played (536), the most saves (13,711) and the best save percentage (.922) in the Bs nearly 100-year franchise history.

Get the latest news and analysis on all of your teams from NBC Sports Bostonby downloading the My Teams App

Even his playoff stats are excellent as Rask ranks seventh all-time in NHL history with a .9268 save percentage in the postseason and is the active leader among all NHL goalies with a .9218 career save percentage in the regular season over his 13-year career.

He ranks third all-time in career save percentage behindDominik Hasek and Johnny Bower, both Hall of Famers. Clearly, the reduced workload paired with Jaroslav Halak has been a big deal to Rask in the last couple of seasons as hes approaching his mid-thirties. The reduced workload led directly to playing at a Vezina Trophy level all season and allowed Rask to carry the Bruins with a .934 save percentage during last springs run to the Stanley Cup Final.

Rask is even beginning to push his way into the Hockey Hall of Fame conversation as the career numbers pile up for him.

But there is an unfinished business element to his decade-long legacy with the Black and Gold after falling short in some extremely big moments for the Bruins during the postseason.

You look at as a process and when youre a young guy, youre just looking to make a name for yourself, said Rask. And then as the years go by you kind of learn different things about your game and about yourself, and what you need to do and what not [to do].

In the years where I needed to play a lot of games I had to focus on keeping my mind sharp and my body rested, and years where I didnt have to play a lot of games then you have more practice time. I think over the years its a balance of keeping your mind and body in sync. And you try to improve your game every day and every year and then before you know it ten years have gone by. You say wow and its been a long time when it doesnt feel like its been that long.

Rask has won a Stanley Cup as a backup to Tim Thomas in 2011, but the Finnish netminder has not been able to carry the Bruins to hockey immortality as the franchise guy. He has yet to get the Bs over the top in two tries at the Stanley Cup Final in 2013 and 2019 and the Bruins enter this postseason as the favorites after winning the Presidents'Trophy during the regular season.

If you look at the way our team is built, were built for a long run into the playoffs, said Rask. Unfortunately, we were heading to a direction when the league, and the whole world, came to a stop. Now we have to go back to building that chemistry with the same group as when it stopped. Obviously, winning a Stanley Cup or any trophy in Boston is a big thing.

Thats something we need to try for and thats our goal. We just have to adapt and build that groove and chemistry back up. The way I look at it is that all bets are off because everybody has been off for the last four months and were starting from scratch.

The Bruins' core group isnt getting any younger and neither is Rask as he enters the final year of his contract with Boston next season, so this may be the last, best chance for all of them to win one more before the championship window begins to close.

If Rask once again falls short this postseason, fair or not, it will cement a legacy that he was never able to carry the Bruins over the Cup threshold as Tim Thomas did almost 10 years ago when he pitched shutouts in Game 7 of both the Eastern Conference Final and then again in the Stanley Cup Final against the Vancouver Canucks. If he's not ready to play after the long layoff and the Bruins exit the postseason quickly, it will be even worse for all parties involved.

If Rask is able to play as he did last postseason, when he would have won the Conn Smythe Trophy had the Bs won Game 7 against St. Louis, and finish it off by playing well when the Bruins need him most in a Game 7-type situation, then it will be the crowning achievement in whats already been an exceptional regular season career. It could mean entry to the Hockey Hall of Fame for Rask, and it certainly would clinch his status as the best goalie in the nearly 100-year history of the Bruins franchise.

But all of it comes down to how things go for the goaltender and the Bs hockey club that takes many of its cues from exactly how he is playing between the pipes.

So, yeah, theres quite a bit riding on how things go for Rask in his go-round for the Bruins in the Stanley Cup playoffs.

See original here:

Haggerty: Rask's legacy will very much be impacted by this playoff run - NBC Sports Boston

From Alissons assist to Origi lobbing Pickford Every Liverpool players best moment of 2019/20 – This Is Anfield

Liverpool sealed immortality in 2019/20, finally winning the Premier League title. But what was each players standout contribution to the season?

Last August, the Reds went into the new campaign as Champions League holders, but the holy grail of a league title had evaded them once more.

What we have witnessed in the 11 months since has been truly remarkable, with 99 points amassed and a worldwide pandemic halting Liverpools title charge for nearly three months.

Jurgen Klopp and his players have gained legendary status forever, with so many individuals coming up with the goods at different times.

Heres what we think was each Liverpool players best moment of 2019/20.

(NB: Excludes those to have made fewer than 10 appearances in all competitions, which rules out the likes of Harvey Elliott, Caoimhin Kelleher and Andy Lonergan.)

Alissons assist against Man United was a standout moment of the entire campaign, as he fired an inch-perfect pass to the onrushing Mohamed Salah.

The Brazilian then raced the full length of the pitch for good measure, producing a world-class knee slide as he celebrated with his team-mate.

Adrian has had an up-and-down first season at Liverpool, but he contributed greatly in the UEFA Super Cup.

The Spaniard saved Tammy Abrahams must-score penalty in the shootout win over Chelsea, sealing yet another trophy for the Reds.

Trent Alexander-Arnolds meteoric rise continued in 2019/20, as he cemented his reputation as one of world footballs most exciting young players.

His performance at Leicester on Boxing Day was arguably the best individual display of the season, with a goal, two assists and a clean sheet to his name.

Neco Williams has come of age this season and he now looks an able deputy to Alexander-Arnold.

The teenager made his Premier League debut against Crystal Palace in Junean immensely proud moment for a huge talent.

Joe Gomez is very much Virgil van Dijks junior partner at the heart of Liverpools defence, but he became the leader in the FA Cup clash with Everton.

He was magnificent in the 1-0 over the Blues, performing immaculately alongside the inexperienced Nat Phillips.

Van Dijk has repeated last seasons brilliance, becoming an ever-present in the Premier League for a second season in a row.

The Dutchmans header at home to United has to be his best moment, although his incredible headed control to himself against Brighton epitomised his class.

Injuries have again disrupted Joel Matips season, but he was in imperious form at the start of the campaign.

The centre-backs bullet header at home to Arsenal in August set Liverpool on their way to a resounding 3-1 victory.

Lovren leaves Anfield this summer and his season was often miss rather than hit.

Thats not to say there havent been key contributions, however, not least in the 3-1 win over Man City at Anfield, when he was a rock at the back.

His brilliant assist against Chelsea comes close, but Andy Robertsons equaliser at Aston Villa in November was a big moment in the season.

Without his header, and the Sadio Mane strike that followed, the title race could so easily have panned out differently on a day when City looked to have narrowed the gap to just four points.

The win over City was a day that highlighted Liverpools superiority over their rivals and Fabinho was a monster in the middle of the park.

The Brazilians stunning strike opened the scoring he would score a similar effort at home to Palace, too.

Theres only one winner here.

Jordan Henderson became the first-ever Liverpool captain to lift the Premier League trophy it is an image that he will be remembered for forever.

That Steven Gerrard-shaped shadow looming over him is no more.

It might not have been pretty, but Gini Wijnaldums winner at Sheffield United was priceless.

The 29-year-olds volley squeezed through the hands of Dean Henderson to send the away end wild, as Liverpool maintained their 100 percent record in gritty fashion.

When it comes to scoring a penalty, would you trust anyone more than James Milner?

The veterans last-gasp spot-kick against Leicester at Anfield was another enormous moment in the title race, as Liverpools relentless march to glory continued.

Naby Keita has been one of Liverpools star men after the restart, having blown hot and cold prior to it.

The Guineans thunderous strike against Chelsea was his best goal yet for the Reds and further suggests he is on the verge of becoming an increasingly key figure.

Alex Oxlade-Chamberlain chipped in with eight goals in 2019/20, including a beauty against former club Arsenal in the League Cup.

It was his gorgeous outside-of-the-foot finish away to Genk that was the pick of the bunch, though, with the shot hitting the underside of the crossbar for good measure.

Adam Lallana departs Liverpool as a hugely popular figure, with his impact off the pitch valued greatly by Klopp.

His late equaliser away to United was crucial in its own right, however, preserving the Reds unbeaten record at the time.

This is an obvious one, isnt it?

Scoring in the Premier League against Villa was a great moment for Curtis Jones, as was netting the winning penalty in front of the Kop against Arsenal in the League Cup.

But both pale into insignificance compared to bagging a brilliant winner at home to Everton in the FA Cup.

A dream moment for any boyhood Red.

Xherdan Shaqiris influence at Liverpool has steadily dwindled, but he has still chipped in sporadically.

The Swiss slid home a lovely finish against Everton in the league, on a night when he was at his unpredictable, entertaining best.

Takumi Minamino has yet to make a noticeable contribution for Liverpool, so we will go with his outstanding performance for Salzburg at Anfield.

It was one of the best displays by an opposition player in years, including a well-taken volley.

The 2-0 win over United felt like the day the title was clinched and Salahs aforementioned goal was the crowning moment of the match.

He latched onto Alissons long pass in supreme fashion, before finishing well past David De Gea in front of an ecstatic Kop.

The celebration wasnt too shabby, either.

Mane is a strong Player of the Year contender, producing so many major contributions along the way.

It is his stoppage-time winner at Villa that will arguably be remembered as Liverpools biggest goal of the season, however, with the Senegalese steering a header into the far corner.

It may not have been the most ruthless season of Roberto Firminos career, but he still scored the goal that clinched the Club World Cup back in December.

The 28-year-old finishing with aplomb in the 1-0 win over Flamengo, further etching his name into Liverpool folklore.

Read the original:

From Alissons assist to Origi lobbing Pickford Every Liverpool players best moment of 2019/20 - This Is Anfield

The dismissible – The News International

The dismissible

When an event is unexplained, it cant be repeated. Cubas astonishing internationalism, the good news of the pandemic, is talked about (outside Cuba) as if a miracle, without cause. Support grows for the Nobel Prize nomination but the justification for the Henry Reeve Brigade, established in 2005, is left out. The explanation is ideas.

It is urgent according to Eddie Glaude in a new book on James Baldwin. Well, he doesnt exactly say that. But for Baldwin, what kind of human beings we aspire to be is most important and the explanation for Cubas success is precisely that. In Zona Roja, Enrique Ubieta Gmez says Cuban medical workers fighting Ebola in 2014 know about existence: We exist interdependently. Ubieta describes Cuban internationalism as an inescapable ethic. Once youve lived it, you cannot not live it. You know human connection a fact of science and you learn its energy.

Ubietas explanation is existential. Baldwin used similar language. In 1963, he wrote, Perhaps the whole root of our trouble, the human trouble, is that we imprison ourselves to deny the fact of death, which is the only fact we have. Glaude supports Baldwins call to begin again, with the America idea, shedding its old ideas. He might look South. Latin American independistas raised precisely Baldwins question: how to resist the lie at the heart of the [imperialist] nation when it is about love, life and death, that is, everything.

Truth is not enough. If Galileo had just provided truths, he wouldnt have been condemned. Galileo became threatening when he made those truths plausible with a larger picture of cosmic humility, contradicting the establishments comforting identity. One thing we might learn from Galileo, according to astrophysicist Mario Livio in a new book, is that he didnt just observe truths and tell stories about them. His phenomenal capacity for abstraction let him see where those truths led.

Truths are easy when unexplained. Consider Olga Tokarczuks 'Flights'. It gives truth about people traveling everywhere escaping their own lives, and then being safely escorted right back to them. We see people running through airports with flushed red faces, their straw hats and souvenir drums and masks and shell necklaces. All this moving around in a chaotic fashion [to] increase their likelihood of being in the right place at the right time even has meaning. A travel psychologist explains that such chaos appears to call into question the existence of a self understood non-relationally.

It is funny to expect deeper meaning regarding people moving around in a chaotic fashion to increase their likelihood of being in the right place at the right time from a travel psychologist at an airport between flights. We laugh because we do in fact expect that, absurdly.

We get truth from 'Flights' but its dismissible. Annushka, for instance, escapes her unbearable life : to go, sway, walk, run, take flight. She finds happiness when she does not have a single thought in her head, a single care, a single expectation or hope. Shes happy, free of her identity, her life, her responsibilities. But she is also cold, hungry, dirty, alone, tired, and homeless. The image is silly.

In fact, the idea underlying it is silly, namely, that to have no thoughts, you should have no identity, no responsibilities. Its as pervasive as friction, from which Galileo abstracted to get truth about inertia. In fact, to be happy with no expectations or hope, as Annushka is, is not silly. But understanding how that is so requires a phenomenal capacity for abstraction from social expectations.

'Flights' doesnt do that. It responds to an expectation identified by Cuban philosopher and diplomat Raul Roa in 1953 as the worlds gravest crisis. It was indeed the America idea: Human beings imprisoned in discrete selves, defined by action and results. It is not humanist, as claimed, Roa argues, because it omits the fact of death, as Baldwin recognized. There were few dissenters to the man of action during the Renaissance, and Roa saw there would now be none because of US power.

Baldwin tried to escape that power by living outside the US. He struggled with what it had made of him. But American power follows one everywhere.

Emily Dickinson, the greatest poet in the English language, abstracts from expectations 'Flights' dignifies. According to biographer Martha Ackman, Dickinson lived as if busyness and travel is not progress. She never apologized for, nor defended, the priority she gave to silence and solitude. As result, we get truth from her poetry: about what it means to be human. For, she was in fact not detached from a world she never visited physically or had any desire to.

She lived as if isolation and detachment are not synonymous. But to know where this leads, you must abstract from the America idea that equates human worth and utility. Comfortably, though, Dickinson is odd Americas most enigmatic and mysterious poet and her way of life therefore dismissible.

'Lord of all the Dead', like 'Flights', leaves comforting old ideas in place. Javier Cercas tells the story of his great-uncle who fought a useless war for Franko. His memoire does give truth but doesnt explain it, so his story, which for him is just a story, cannot itself explain, and is dismissible.

Achilles in 'The Odyssey' is lord of all the dead because he died young and beautiful, and gained immortality. That his great uncle was politically mistaken, theres no doubt. But was he a human failure? Cercas answer is no. At one level, Cercas rejects the Greeks ideal of beautiful death because it denies the existential reality of decrepitude: There is no escaping it. But on the other hand, Cercas assumes the separation of mind and body that makes beautiful death worth speculating about: the idea that the body decays and that the mind somehow escapes natures universal laws of causation.

He ends the book speculating about immortality. Nobody dies, he writes. Were just transformed, physically. He himself, at the book's end, is in the eternal present. It doesnt explain what needs to be explained, given the real story of this book which is what Cercas calls the silent wake of hatred, resentment and violence left over by the war. The silent wake is explained by ignorance precisely of shared humanity Cercas names but doesnt explain. It is decrepitude: the fact of death.

It is known by every human being. Cercas tells a story about his great uncle but denies the significance of that story because he tells it with the old ideas in place, the ones Glaude says need to be shed, like swaddling clothes to begin again as Baldwin urged. Glaude is not sure it can happen. But it has happened. Thats the good news about the Henry Reeve Medical brigade, if it were explained.

On Friday, March 20, Cuban president, Miguel Diaz-Canel, speaking nationally, outlined new measures to slow the pandemic. The good news, he said, is that Cuban people supported the decision to accept the Braemar, a UK cruise ship refused docking elsewhere because of infected passengers. A century ago, another ship sought aid from Cuba. Its passengers were Jews. It was turned away.

That, Diaz-Canel said, was before the Revolution. The good news was the expectation that the Braemar should be helped. That expectation is the success of the Cuban revolution. It explains the Henry Reeve Brigade. Expectations come from practises, from what is lived. Diaz-Canel then said, one day the truth will be known. But what truth?

Excerpted from: 'Cubas Nobel Nomination and Baldwins Call to Begin Again'.

Courtesy: Counterpunch.org

Read this article:

The dismissible - The News International

Sacred Islands Of Exotic Eastern Gods And Elixir Of The Immortals – Ancient Origins

Classic works such as Odyssey by Homer, The Tempest by William Shakespeare and Robinson Crusoe by Daniel Defoe tell about mysterious distant islands. These islands are usually exotic and inaccessible homes to treasures, spirits and immortals - providing the heroes with many strange adventures. From at least the third century BC, the Chinese culture regarded islands as sacred homes to the elixir of immortality. All these enticements then inspired a trend of voyages in search of sacred islands.

The early history of the quests in search of the sacred islands to gain immortality came to dominate imperial Chinese folklore of islands and the ocean. The narrative style of these quests first developed in the Ancient Chinese Classic of Mountains and Seas , acompilation of Chinese mythology, mythical geographyand cultural account of pre-QinChina.As Chinas maritime activity increased, fictions about islands of adventure gained popularity. This trend, in turn, inspired another trend of constructing artificial islands in imperial palace gardens.

Mount Penglai (Mountain of Immortals) by Tomioka Tessai (1924) ( Public Domain )

An influential fourth century BC Chinesephilosopher, Zhuang Zhou, tells of the immortals. The immortals are perfect beings who dwell in faraway islands, celebrated in poetry and paintings for their beauty and bountiful nature.

These islands became a favorite subject of Chinese and Japanese landscape painting. They had neither winter nor misery. However, they had high mountains, lush vegetation, clear blue waters as well as beautiful flora and fauna. The plants in these islands had magical qualities such as restoring youth and offering immortality to those who consume them. Other magical richness included waters of life, life-prolonging trees and enchanted fruits that can heal any ailment, grant eternal youth and even raise the dead.

The three most famous islands in Qin and Han Dynasty literary works are Penglai, Fangzhang and Yingzhou. Reports of these three sacred islands first appear in the late second centuryBC Taishi Official Book , better known as Records of the Grand Historian in which King Wei, King Xuan of Qi State, and King Zhao of Yan State sent their officials to look for the three sacred islands - Penglai, Fangzhang, and Yingzhou.

Penglai (detail), depiction of one of the mythical islands by Yuan Yao (18th century) ( Public Domain )

Seen from afar, the islands are covered in clouds. When regular people approached these islands, a disastrous wind would hit and force the boat to leave

READ MORE

Like this Preview and want to read on? You can! JOIN US THERE (with easy, instant access ) and see what youre missing!! All Premium articles are available in full, with immediate access.

For the price of a cup of coffee, you get this and all the other great benefits at Ancient Origins Premium.And - each time you support AO Premium, you support independent thought and writing.

Martini Fisher is a Mythographer and author of many books, including Time Maps: Gods, Kings and Prophets | Check out MartiniFisher.com

Top Image : A 19th century ukiyo-e by Kuniyoshi depicting the ships of the great sea expedition sent around 219 BC by the first Chinese Emperor, Qin Shi Huang, to find the legendary home of the immortals, the Mount Penglai, and retrieve the elixir of immortality. ( Public Domain)

ByMartini Fisher

Read the original here:

Sacred Islands Of Exotic Eastern Gods And Elixir Of The Immortals - Ancient Origins

Hack job? What’s the deal with David Pastrnak’s latest tweet? – NBC Sports Boston

Its no stretch to say that a great deal of Tuukka Rasks ultimate legacy with the Bruins is tied up in the unprecedented 2020 Stanley Cup playoffs inside the bubble.

Sure, the 33-year-old is a Vezina Trophy finalist this season for the second time in his NHL career and is essentially in a two-man race with Winnipegs Connor Hellebuyck for the ultimate piece of goaltending hardware this season. The .929 save percentage and NHL-leading 2.25 goals against average speak for themselves about his dominance this year while largely splitting time with backup goalie Jaroslav Halak in a nearly equal split of playing time.

Truthfully, the regular season accolades go on and on for Rask as he continues to prove hes the best regular season goaltender in Bruins franchise history. Hes the all-time winningest goalie in Bruins history with 291 wins, and has the most games played (536), the most saves (13,711) and the best save percentage (.922) in the Bs nearly 100-year franchise history.

Get the latest news and analysis on all of your teams from NBC Sports Bostonby downloading the My Teams App

Even his playoff stats are excellent as Rask ranks seventh all-time in NHL history with a .9268 save percentage in the postseason and is the active leader among all NHL goalies with a .9218 career save percentage in the regular season over his 13-year career.

He ranks third all-time in career save percentage behindDominik Hasek and Johnny Bower, both Hall of Famers. Clearly, the reduced workload paired with Jaroslav Halak has been a big deal to Rask in the last couple of seasons as hes approaching his mid-thirties. The reduced workload led directly to playing at a Vezina Trophy level all season and allowed Rask to carry the Bruins with a .934 save percentage during last springs run to the Stanley Cup Final.

Rask is even beginning to push his way into the Hockey Hall of Fame conversation as the career numbers pile up for him.

But there is an unfinished business element to his decade-long legacy with the Black and Gold after falling short in some extremely big moments for the Bruins during the postseason.

You look at as a process and when youre a young guy, youre just looking to make a name for yourself, said Rask. And then as the years go by you kind of learn different things about your game and about yourself, and what you need to do and what not [to do].

In the years where I needed to play a lot of games I had to focus on keeping my mind sharp and my body rested, and years where I didnt have to play a lot of games then you have more practice time. I think over the years its a balance of keeping your mind and body in sync. And you try to improve your game every day and every year and then before you know it ten years have gone by. You say wow and its been a long time when it doesnt feel like its been that long.

Rask has won a Stanley Cup as a backup to Tim Thomas in 2011, but the Finnish netminder has not been able to carry the Bruins to hockey immortality as the franchise guy. He has yet to get the Bs over the top in two tries at the Stanley Cup Final in 2013 and 2019 and the Bruins enter this postseason as the favorites after winning the Presidents'Trophy during the regular season.

If you look at the way our team is built, were built for a long run into the playoffs, said Rask. Unfortunately, we were heading to a direction when the league, and the whole world, came to a stop. Now we have to go back to building that chemistry with the same group as when it stopped. Obviously, winning a Stanley Cup or any trophy in Boston is a big thing.

Thats something we need to try for and thats our goal. We just have to adapt and build that groove and chemistry back up. The way I look at it is that all bets are off because everybody has been off for the last four months and were starting from scratch.

The Bruins' core group isnt getting any younger and neither is Rask as he enters the final year of his contract with Boston next season, so this may be the last, best chance for all of them to win one more before the championship window begins to close.

If Rask once again falls short this postseason, fair or not, it will cement a legacy that he was never able to carry the Bruins over the Cup threshold as Tim Thomas did almost 10 years ago when he pitched shutouts in Game 7 of both the Eastern Conference Final and then again in the Stanley Cup Final against the Vancouver Canucks. If he's not ready to play after the long layoff and the Bruins exit the postseason quickly, it will be even worse for all parties involved.

If Rask is able to play as he did last postseason, when he would have won the Conn Smythe Trophy had the Bs won Game 7 against St. Louis, and finish it off by playing well when the Bruins need him most in a Game 7-type situation, then it will be the crowning achievement in whats already been an exceptional regular season career. It could mean entry to the Hockey Hall of Fame for Rask, and it certainly would clinch his status as the best goalie in the nearly 100-year history of the Bruins franchise.

But all of it comes down to how things go for the goaltender and the Bs hockey club that takes many of its cues from exactly how he is playing between the pipes.

So, yeah, theres quite a bit riding on how things go for Rask in his go-round for the Bruins in the Stanley Cup playoffs.

View post:

Hack job? What's the deal with David Pastrnak's latest tweet? - NBC Sports Boston

Peaches are now in season; here’s a recipe to enjoy the fruit with a savory salad – Fly Magazine

A ripe peach tender to the touch, floral and honeyed in the nose, slurpy on first bite is a sensory experience like few others. And that river of nectar flooding the tongue? For a few minutes, I am a hummingbird in flight, buzzing with unbridled joy.

If you can relate, then you know that the way to eat a peach in unadulterated bliss is over the sink just you and the peach having a moment with the juices running down your arms and the faucet at the ready for clean-up duty.

For many a peach lover, baking cobbler, churning ice cream and putting up jam are summertime traditions. Personally, I find the peach so teeth-tingling sweet in its natural state that I crave little adornment. Unless, of course, were going savory.

In fact, that inherent sweetness plays well with big and bold flavors typically reserved for the savory world including fresh basil and mint, chile peppers, onions and ginger root. Peaches like the smoke of charcoal and enjoy being grilled themselves or paired with grilled chicken, pork or shrimp.

Just days ago, I got to see for myself just how far savory I could take the sweet peach. Inspiration came while leafing through my dog-eared copy of Ripe, an ode to fruit by British food writer Nigel Slater.

In his essay on peaches, Slater shares, in his signature notebook style, a recipe for a peach-forward salad amped up with bold and beautiful basil and mint, sweet peppers and a kicky Viet-style dressing of fish sauce, limes and chile peppers.

Slater calls for shredded chicken, which is delightful, but if chicken is neither interesting nor available, the salad will still be a riot of color and flavor. Its that good.

As I built the salad, I added cucumber, a few cherry tomatoes and raw peanuts, along with some backyard romaine to line our plates. My husband envisions a side of rice or rice noodles for the next time. And as long as peaches are gracing farmstand shelves, there will definitely be a next time.

A salad of peaches and herbs (and maybe chicken) with a Viet-style dressing

Adapted from Ripe by Nigel Slater.

Makes 4 servings.

Success! An email has been sent with a link to confirm list signup.

Error! There was an error processing your request.

Preheat the oven to 400 F.

In a small bowl, stir together the spices and oil, and rub all over the chicken. Place on a sheet pan or in a baking dish and roast until golden and cooked through, about 30 minutes. (This step can also be done on the grill and can be done in advance.) Remove the oven and let cool while you prep the rest of the salad.

Make the dressing: In a small bowl, stir together the fish sauce, lime and sugar with a fork until the sugar is dissolved. Add the chile pepper and scallions, stir and set aside under ready to serve. The flavors deepen as the dressing sits.

Slice the peaches in half, remove the pits and cut into 1/2-inch slices. Transfer to a large bowl. Add the pepper strips and the herbs. Resist the urge to stir.

Shred or thinly slice the chicken off the bone and add to the peach mixture. Add any of the optional add-ons and gently stir until evenly distributed.

When ready to serve, gradually add half of the dressing, stirring until well coated.

If using the lettuce, lay on a platter or on the bottom of a bowl, then place salad on top. Sprinkle with peanuts, if using, and bring the remaining dressing to the table.

The peach is an ancient Chinese relic, dating to fifth century B.C. when it was mentioned throughout a collection of poetry by Confucius. The peach was highly revered and continues to play an important role in the folklore of the Chinese people. Known as tao, the peach is the most

sacred plant of the Chinese Taoists, and is considered a magic fruit and a symbol of immortality, reflected in the Peach Blossom Spring, an essay by a Chinese poet during the fourth century B.C.

From China, the peach traveled to Persia and then onto Greece, and into the rest of Europe, thanks to peach lover Alexander the Great.

The peach came to Mexico in the early to mid-1500s via Spanish explorers. Throughout the 1600s, the peach traveled north from coastal Georgia and north Florida and was cultivated in the colonies of Virginia, Maryland and New Jersey.

First things first: Inhale (with social distancing in mind, of course). If you don't catch a whiff of that signature perfume, move on to the next peach. A ready-to-eat peach should be fragrant and invite you in.

For immediate consumption, choose fruit that has some tactile give, (similar to the fleshy part of your palm), but also that is free of bruises and boo-boos. On the other hand, if a peach is rock hard, it probably has been picked too early often the case for long-distance fruit and should be left behind.

Even for less-than-perfectly-ripe fruit, carefully transport your precious cargo home because it is highly perishable. I remember from my days working a fruit stand how wed have to pay special attention to the peaches on hot days to make sure they did not grow moldy beards.

Once home, keep peaches out of the refrigerator and out of direct sunlight. On the other hand, to buy some time for a ripe peach, stick it in the refrigerator, where it stops ripening. Caveat: Refrigeration invites moisture and shriveling.

Although tempting to place several almost-ripe peaches in a pretty bowl, keep in mind that they can mold even if rubbing up against each other.

Freeze for later

If peach season feels too short, consider freezing a bunch for later. Unlike berries, which can be frozen individually, peaches need a little more processing before the deep freeze. Drop the fruit into boiling water for about 45 seconds then into a bowl of ice water. This helps ease peeling, which is recommended. Once cool, slice in half and remove the pit. Cut each half into two or three pieces and place on a sheet pan to dry. Drizzle a small amount of fresh lemon juice on top and place in freezer until solid. Pack in freezer-safe containers or bags.

Subscribe today for only $2

' + submsgtxthtml + '

Get unlimited access to breaking news, ancestry archives, our daily E-newspaper, games and more.

Subscribe today for only $2

' + submsgtxthtml + '

Get unlimited access to breaking news, ancestry archives, our daily E-newspaper, games and more.

Subscribe today for only $2

' + submsgtxthtml + '

Get unlimited access to breaking news, ancestry archives, our daily E-newspaper, games and more.

Subscribe today for only $2

' + submsgtxthtml + '

The rest is here:

Peaches are now in season; here's a recipe to enjoy the fruit with a savory salad - Fly Magazine